The case for & against
Bull & Bear analysis
Bullish
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for urological cancers and neuropsychiatry conditions. The company’s lead product, NDVO-1, targets non-muscle invasive bladder cancer (NMIBC) and aims to become a best-in-class treatment option thanks to its sustained-release formulation. Relmada’s portfolio reflects its commitment to addressing significant unmet medical needs while navigating a competitive landscape within oncology and central nervous system disorders.
Bull says
- ↑$234M cash balance funds operations through 2029, up from $94M YoY
- ↑76% overall response rate (80% in BCG-unresponsive patients) at 12-month follow-up
- ↑Phase III trial for NDVO-1 starts mid-2026 targeting ~75k annual intermediate-risk patients
- ↑FDA alignment and sustained-release formulation position NDVO-1 as best-in-class challenger to BCG
- ↑High growth and momentum factors with strong institutional ownership signal investor interest
- ↑Sustained-release NDVO-1 offers simpler administration and lower toxicity versus existing therapies
Bear says
- ↓Net loss widened to $19.1M in Q1 2026 from $17.6M, underlining cash burn pressure
- ↓High leverage and debt levels heighten vulnerability to interest-rate hikes
- ↓Negative profitability factors persist, requiring additional financing beyond 2029
- ↓FDA approval not guaranteed; Phase III execution and long-term efficacy remain uncertain
- ↓Crowded NMIBC market with UroGen, Merck and others challenging NDVO-1 adoption
- ↓Analyst revisions trend downward, reflecting skepticism over near-term revenue and milestones
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-02-2026neutral
Transcript signals
Bull points
- 2025 is off to a good start for RealMata. We had the two unique product candidates with very encouraging Phase II data and large addressable markets to our portfolio, MDV01 for bladder cancer and Cepranolone, for Prader-Willi syndrome, Tourette syndrome, and potentially other CNS indications.
- With two innovative product candidates that have shown promising proof of concept data, 27 million cash balance, clean balance sheet, and a disciplined approach to development plan, we are in a good position to advance our pipeline to important clinical milestones.
- We believe that the results suggest that NDVO1 has the potential to significantly improve the care of patients with NM-IBC.
Bear points
- As of March 31, 2025, RealMata had cash, cash equivalents, and short-term investments of approximately $27.1 million, compared to $44.9 million as of December 31, 2024.
- Cash used in operations in the first quarter ended March 31, 2025, was $18.1 million compared to $13 million for the same period in 2024.
- As of March 31, 2025, RealMata had cash, cash equivalents, and short-term investments of approximately $27.1 million, compared to $44.9 million as of December 31, 2024.
Read full transcript analysis ›